The global injection pen market was valued at USD 37.80 Billion in 2024 driven by the rising prevalence of chronic diseases and growing demand for self-administration devices across the globe. It is expected to grow at a CAGR of 7.20% during the forecast period of 2025-2034 and attain a market value of USD 75.76 Billion by 2034.
Other companies include Becton, Dickinson and Company, Eli Lilly and Company, Ypsomed AG, Biocon Biologics Limited, Owen Mumford Ltd, and Merck KGaA.
This product will be delivered within 3-5 business days.
Injection Pen Market Overview
Injection pens are innovative medical devices designed for precise, user-friendly drug administration, widely used for conditions like diabetes, osteoporosis, and growth hormone deficiencies. The market is driven by the rising prevalence of chronic diseases and the growing demand for self-administration solutions. Key trends include advancements in smart pens and strategic collaborations. These factors, coupled with increased patient convenience are propelling the growth and adoption of injection pens globally.Injection Pen Market Growth Drivers
Rising Prevalence of Chronic Disease Drives Market Growth
The rising prevalence of chronic disease significantly boosts the demand for injection pens. It offers an easy-to-use, patient-friendly solution, allowing for self-administration and improved adherence to treatment regimens. According to the World Health Organization 2023 data, non-communicable or chronic diseases were responsible for approximately 41 million deaths annually, accounting for 74% of all global fatalities. As conditions like diabetes, and rheumatoid arthritis become more common, patients require consistent and convenient administration of biologics and insulin therapies.Injection Pen Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.Expanding Applications to Drive Market Value
One of the key market trends include the expansion of the applications, which is driving growth in the market. For instance, in November 2024 Swiss company Ypsomed secured a contract with Novo Nordisk to supply injection pens for its promising obesity drug, CagriSema, poised to outperform Wegovy in weight loss. This highlighted Novo's commitment to its GLP-1 pipeline, with Ypsomed expanding its production capabilities to meet rising demand by 2025.Strategic Collaborations to Boost Injection Pen Market Growth
Strategic collaborations are driving growth in the market significantly. For instance, in February 2023, Glooko partnered with Sanofi to enhance diabetes management by integrating SoloSmart with the Glooko® platform. SoloSmart, a connected device for SoloStar and DoubleStar insulin pens, tracks insulin doses, dates, and times, enabling data sharing with healthcare professionals. This collaboration aimed to expand digital solutions to over 8,000 clinics globally. Such applications are expected to promote market growth in the forecast period significantly.Surge in FDA Approvals to Strengthen Injection Pen Market Size
In February 2023, Amgen and AstraZeneca’s TEZSPIRE injection pen received FDA approval for self-administration in a pre-filled, single-use setting. set to transform the injection pen market for severe asthma treatments. This approval, based on results from the PATHFINDER clinical trial program, allowed patients greater flexibility to administer TEZSPIRE at home. Such approvals are projected to significantly boost market growth by enhancing patient compliance and expanding treatment accessibility.Increasing Demand for Self-Administration Devices to Boosting Injection Pen Market Value
One of the significant market trends is an increasing demand for self-administration devices among patients. It is driven by a growing focus on patient empowerment and convenience. As more biologics and other treatments become available for self-injection, patients are seeking easier-to-use, at-home solutions. This trend is further supported by advancements in technology, leading to the development of more ergonomic, user-friendly injection pens that enhance the overall patient experience.Injection Pen Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Disposable
- Re-Usable
Market Breakup by Therapy
- Diabetes
- Insulin
- GLP-1
- Growth Hormone Therapy
- Osteoporosis
- Fertility
- Others
Market Breakup by End User
- Home Care Settings
- Hospitals
- Speciality Clinics
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Injection Pen Market Share
Market Share by Type to Witness Significant Growth
Based on the type, the market is divided into disposable and re-usable. Among these, disposable is expected to lead the market during the forecast period, owing to a rise in the adoption of disposable injection pens across the globe. In addition, there is a focus on preventing the risk of cross-contamination and needle stick injuries associated with reusable injection pens. As healthcare professionals and patients prioritize safety, the demand for disposable type is likely to rise steadily in the forecast period.Injection Pen Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. Among these, North America is expected to dominate the market due to the presence of robust healthcare infrastructure and the prominent key players in the region. Companies like Novo Nordisk and Sanofi are heavily investing in research and development to come up with innovative products.Leading Players in the Injection Pen Market
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:Pfizer Inc
Established in 1849, Pfizer is headquartered in New York, USA. The company has developed the Genotropin Pen, an advanced injection pen for administering human growth hormone therapy. The pen simplifies dosage adjustments and ensures precise delivery, offering convenience and improved treatment adherence for patients requiring growth hormone replacement therapy.Novartis AG
Founded in 1996 and headquartered in Basel, Switzerland, Novartis developed the Revolizer, a reusable injection pen system designed for delivering respiratory drugs. This innovative device enhances dose accuracy and patient convenience, supporting its commitment to improving drug delivery solutions across multiple therapeutic areas.Novo Nordisk A/S
Founded in 1923, Novo Nordisk A/S is headquartered in Denmark. The company is renowned for its FlexTouch and FlexPen insulin pens, which are widely used for diabetes management. These pens ensure accurate insulin delivery, ease of use, and enhanced patient compliance, establishing Novo Nordisk as a leader in the market.Sanofi SA
Established in 1973, Sanofi SA is headquartered in Paris, France. The company has developed the SoloStar insulin injection pen, a widely used device for managing diabetes. The pen is designed for precision, convenience, and ease of use, helping patients maintain effective glucose control and improving their overall diabetes management experience.Other companies include Becton, Dickinson and Company, Eli Lilly and Company, Ypsomed AG, Biocon Biologics Limited, Owen Mumford Ltd, and Merck KGaA.
Key Questions Answered in the Injection Pen Market
- What was the global injection pen market value in 2024?
- What is the global injection pen market forecast outlook for 2025-2034?
- What are the regional markets covered in the report?
- What is the market segmentation based on the type?
- What is the market breakup based on the therapy?
- What is the market segmentation based on the end user?
- What are the major factors aiding the global injection pen market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global injection pen market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the global injection pen market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Global Injection Pen Market Overview
4 Vendor Positioning Analysis
5 Global Injection Pen Market Landscape*
6 Global Injection Pen Market Dynamics
7 Global Injection Pen Market Segmentation (218-2034)
8 North America Injection Pen Market (218-2034)
9 Europe Injection Pen Market (218-2034)
10 Asia Pacific Injection Pen Market (218-2034)
11 Latin America Injection Pen Market (218-2034)
12 Middle East and Africa Injection Pen Market (218-2034)
13 Regulatory Framework
14 Patent Analysis
15 Funding and Investment Analysis
16 Strategic Initiatives
17 Supplier Landscape
18 Global Injection Pen Market - Distribution Model (Additional Insight)
Companies Mentioned
- Pfizer Inc.
- Novartis AG
- Novo Nordisk A/S
- Sanofi SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 400 |
Published | June 2025 |
Forecast Period | 2025 - 2034 |
Estimated Market Value ( USD | $ 37.8 Billion |
Forecasted Market Value ( USD | $ 75.76 Billion |
Compound Annual Growth Rate | 7.2% |
Regions Covered | Global |
No. of Companies Mentioned | 4 |